文献速递心脑血管急症消化、代谢与肾脏急症

他汀类药物用于成人心血管疾病预防:美国预防服务工作组证据报告与系统评价

Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2016-01-01
一句话结论在无既往心血管事件的成人中,他汀治疗与全因死亡、心血管死亡及心血管事件风险降低相关,基线风险越高绝对获益越大。

该系统评价纳入19项随机临床试验(n=71 344),比较他汀与安慰剂或不他汀治疗在无既往心血管事件成人中的获益与危害。他汀治疗与全因死亡(RR 0.86)、心血管死亡(RR 0.69)、卒中(RR 0.71)、心肌梗死(RR 0.64)及复合心血管结局(RR 0.70)风险降低相关。相对获益在人口学和临床亚组中似乎一致,包括总胆固醇<200 mg/dL的人群;绝对获益在基线风险更高的亚组中更大。他汀与严重不良事件、肌痛或肝脏相关危害风险增加无关;汇总分析中他汀与糖尿病风险增加无关(RR 1.05),但存在统计异质性(I2=52%),且1项试验发现高强度他汀与糖尿病风险增加相关(RR 1.25)。

要点

  • 在无既往心血管事件的成人中,他汀治疗与全因死亡风险降低相关(RR 0.86,95%CI 0.80-0.93;I2=0%)。
  • 他汀治疗与心血管死亡(RR 0.69)、卒中(RR 0.71)、心肌梗死(RR 0.64)及复合心血管结局(RR 0.70)风险降低相关。
  • 相对获益在包括总胆固醇<200 mg/dL在内的人口学和临床亚组中似乎一致,绝对获益在基线风险更高的亚组中更大。
  • 他汀与严重不良事件(RR 0.99)、肌痛(RR 0.96)或肝脏相关危害(RR 1.10)风险增加无关。
  • 汇总分析中他汀与糖尿病风险增加无关(RR 1.05,95%CI 0.91-1.20),但异质性I2=52%,且1项试验发现高强度他汀与糖尿病风险增加相关(RR 1.25,95%CI 1.05-1.49)。

适用人群与场景

  • 无既往心血管事件的成人,来自19项随机临床试验,平均年龄51-66岁,样本量范围95-17 802。

研究设计与关键结果

  • 系统评价与荟萃分析纳入19项随机临床试验(n=71 344),比较他汀与安慰剂或不他汀治疗在无既往心血管事件成人中的效果。
  • 他汀治疗与全因死亡风险降低相关(RR 0.86,95%CI 0.80-0.93;I2=0%;绝对风险差-0.40%,95%CI -0.64%至-0.17%)。
  • 他汀治疗与心血管死亡风险降低相关(RR 0.69,95%CI 0.54-0.88;I2=54%;绝对风险差-0.43%,95%CI -0.75%至-0.11%)。
  • 他汀治疗与卒中风险降低相关(RR 0.71,95%CI 0.62-0.82;I2=0;绝对风险差-0.38%,95%CI -0.53%至-0.23%)。
  • 他汀治疗与心肌梗死风险降低相关(RR 0.64,95%CI 0.57-0.71;I2=0%;绝对风险差-0.81%,95%CI -1.19%至-0.43%)。
  • 他汀治疗与复合心血管结局风险降低相关(RR 0.70,95%CI 0.63-0.78;I2=36%;绝对风险差-1.39%,95%CI -1.79%至-0.99%)。
  • 他汀与严重不良事件风险增加无关(RR 0.99,95%CI 0.94-1.04)、与肌痛风险增加无关(RR 0.96,95%CI 0.79-1.16)、与肝脏相关危害风险增加无关(RR 1.10,95%CI 0.90-1.35)。
  • 汇总分析中他汀与糖尿病风险增加无关(RR 1.05,95%CI 0.91-1.20),但存在统计异质性(I2=52%);1项试验发现高强度他汀与糖尿病风险增加相关(RR 1.25,95%CI 1.05-1.49)。

证据类型、等级与局限

  • 证据类型:针对美国预防服务工作组的系统评价与荟萃分析,纳入19项随机临床试验。
  • 局限性:汇总分析中糖尿病结局存在统计异质性(I2=52%);无试验直接比较滴定与固定剂量他汀;基于他汀强度未见明确差异。

对床旁实践的改变

  • 在无既往心血管事件的成人中,他汀治疗与全因死亡、心血管死亡及心血管事件风险降低相关,基线风险更高的患者绝对获益更大。
  • 相对获益在包括总胆固醇<200 mg/dL在内的人口学和临床亚组中似乎一致。
  • 他汀与严重不良事件、肌痛或肝脏相关危害风险增加无关;汇总分析中与糖尿病风险增加无关,但存在异质性,且1项试验发现高强度他汀与糖尿病风险增加相关。

指南或共识出处

  • 美国预防服务工作组证据报告与系统评价,发表于JAMA。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Cardiovascular disease (CVD), the leading cause of mortality and morbidity in the United States, may be potentially preventable with statin therapy.

OBJECTIVE: To systematically review benefits and harms of statins for prevention of CVD to inform the US Preventive Services Task Force.

DATA SOURCES: Ovid MEDLINE (from 1946), Cochrane Central Register of Controlled Trials (from 1991), and Cochrane Database of Systematic Reviews (from 2005) to June 2016.

STUDY SELECTION: Randomized clinical trials of statins vs placebo, fixed-dose vs titrated statins, and higher- vs lower-intensity statins in adults without prior cardiovascular events.

DATA EXTRACTION AND SYNTHESIS: One investigator abstracted data, a second checked data for accuracy, and 2 investigators independently assessed study quality using predefined criteria. Data were pooled using random-effects meta-analysis.

MAIN OUTCOMES AND MEASURES: All-cause mortality, CVD-related morbidity or mortality, and harms.

RESULTS: Nineteen trials (n = 71 344 participants [range, 95-17 802]; mean age, 51-66 years) compared statins vs placebo or no statin. Statin therapy was associated with decreased risk of all-cause mortality (risk ratio [RR], 0.86 [95% CI, 0.80 to 0.93]; I2 = 0%; absolute risk difference [ARD], -0.40% [95% CI, -0.64% to -0.17%]), cardiovascular mortality (RR, 0.69 [95% CI, 0.54 to 0.88]; I2 = 54%; ARD, -0.43% [95% CI, -0.75% to -0.11%]), stroke (RR, 0.71 [95% CI, 0.62 to 0.82]; I2 = 0; ARD, -0.38% [95% CI, -0.53% to -0.23%]), myocardial infarction (RR, 0.64 [95% CI, 0.57 to 0.71]; I2 = 0%; ARD, -0.81% [95% CI, -1.19 to -0.43%]), and composite cardiovascular outcomes (RR, 0.70 [95% CI, 0.63 to 0.78]; I2 = 36%; ARD, -1.39% [95% CI, -1.79 to -0.99%]). Relative benefits appeared consistent in demographic and clinical subgroups, including populations without marked hyperlipidemia (total cholesterol level <200 mg/dL); absolute benefits were higher in subgroups at higher baseline risk. Statins were not associated with increased risk of serious adverse events (RR, 0.99 [95% CI, 0.94 to 1.04]), myalgias (RR, 0.96 [95% CI, 0.79 to 1.16]), or liver-related harms (RR, 1.10 [95% CI, 0.90 to 1.35]). In pooled analysis, statins were not associated with increased risk of diabetes (RR, 1.05 [95% CI, 0.91 to 1.20]), although statistical heterogeneity was present (I2 = 52%), and 1 trial found high-intensity statins associated with increased risk (RR, 1.25 [95% CI, 1.05 to 1.49]). No trial directly compared titrated vs fixed-dose statins, and there were no clear differences based on statin intensity.

CONCLUSIONS AND RELEVANCE: In adults at increased CVD risk but without prior CVD events, statin therapy was associated with reduced risk of all-cause and cardiovascular mortality and CVD events, with greater absolute benefits in patients at greater baseline risk.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Chou R, Dana T, Blazina I, et al. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016. PMID: 27838722. doi:10.1001/jama.2015.15629

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。